Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 10/20 | 0.44 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 3/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | USP7 | Q93009 | 1/20 | 0.34 |
| ▸ | SPAST | Q9UBP0 | 1/20 | 0.34 |
| ▸ | WEE1 | P30291 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16391504 | 1.00 | HTR2C (0.44) | HTR2CSOS1HTR2AHTR3AUSP7 | |
| SCHEMBL16392053 | 0.86 | HTR2C (0.43) | HTR2CHTR2AHTR3ASPASTWEE1 | |
| SCHEMBL17744534 | 0.86 | HTR2C (0.43) | HTR2CHTR2AHTR3ASPASTWEE1 | |
| SCHEMBL17744458 | 0.86 | HTR2C (0.41) | HTR2CHTR2AHTR3ASPAST | |
| SCHEMBL16391528 | 0.86 | HTR2C (0.41) | HTR2CHTR2AHTR3ASPAST | |
| SCHEMBL17744495 | 0.82 | LATS1 (0.47) | HTR2CSOS1USP7WEE1 | |
| SCHEMBL16391455 | 0.82 | LATS1 (0.47) | HTR2CSOS1USP7WEE1 | |
| SCHEMBL16391595 | 0.81 | HTR2C (0.39) | HTR2CHTR2AUSP7WEE1 | |
| SCHEMBL17744437 | 0.81 | HTR2C (0.39) | HTR2CHTR2AUSP7WEE1 | |
| SCHEMBL16391381 | 0.81 | HTR2C (0.44) | HTR2CHTR2AWEE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3020718-B1 | NOVEL PDE4 INHIBITOR | MEIJI SEIKA PHARMA CO LTD (JP) | 2018-12-26 | — | — | EP | claimed |
| US-9890142-B2 | PDE4 inhibitor | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-02-13 | — | — | US | claimed |
| US-9850235-B2 | — | — | 2017-12-26 | — | — | US | claimed |
| US-20160159783-A1 | PDE4 Inhibitor | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-06-09 | — | — | US | claimed |
| EP-3020718-B1 | NOVEL PDE4 INHIBITOR | MEIJI SEIKA PHARMA CO LTD (JP) | 2018-12-26 | — | — | EP | disclosed |
| US-9890142-B2 | PDE4 inhibitor | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-02-13 | — | — | US | disclosed |
| US-9850235-B2 | — | — | 2017-12-26 | — | — | US | disclosed |
| US-20160159783-A1 | PDE4 Inhibitor | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159783-A1 | PDE4 Inhibitor | PDE4A, PDE4B, PDE3B | HTR2C 3334/4885SOS1 2592/4885HTR2A 3249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.